Eclipse Regenesis
Eclipse Regenesis is dedicated to pioneering tissue regeneration therapies for Short Bowel Syndrome (SBS). Their mission is to develop innovative treatments that improve nutrient absorption and enhance the quality of life for SBS patients. They collaborate with leading healthcare organizations and focus on advancing regenerative medicine to offer sustainable solutions for those affected by SBS. The company is actively involved in research and development, including securing grants such as the NSF SBIR grant to develop minimally-invasive therapies like the Eclipse XL1 System, which promotes intestinal tissue growth through distraction enterogenesis. They also focus on comprehensive patient care, including managing nutrition, TPN, ostomy, and G-tube care, and supporting families through education and community support networks.
Industries
Nr. of Employees
small (1-50)
Eclipse Regenesis
123 Regenesis Lane, Innovation City, State, ZIP
Products
Implantable intestinal tissue-regeneration device (under development)
An implantable mechanical device designed to stimulate growth of functional intestinal tissue to increase absorptive surface area for patients with intestinal insufficiency; currently under preclinical and early development and not available for clinical use.
Implantable intestinal tissue-regeneration device (under development)
An implantable mechanical device designed to stimulate growth of functional intestinal tissue to increase absorptive surface area for patients with intestinal insufficiency; currently under preclinical and early development and not available for clinical use.
Services
Online articles, guides, and blog content covering Short Bowel Syndrome education, nutrition strategies, TPN and catheter care, ostomy and G-tube management, school/lifestyle adaptation, and psychosocial support.
Strategic collaborations with academic medical centers and participation in translational innovation programs to support device development, preclinical research, and grant-funded activities.
Online articles, guides, and blog content covering Short Bowel Syndrome education, nutrition strategies, TPN and catheter care, ostomy and G-tube management, school/lifestyle adaptation, and psychosocial support.
Strategic collaborations with academic medical centers and participation in translational innovation programs to support device development, preclinical research, and grant-funded activities.
Expertise Areas
- Intestinal regenerative medicine and distraction enterogenesis
- Implantable medical device design and preclinical development
- Early-stage clinical development and translational research
- Parenteral and enteral nutrition management
Key Technologies
- Distraction enterogenesis (mechanical intestinal lengthening)
- Tissue engineering and regenerative therapies
- Endoscopic and minimally-invasive device development
- Preclinical models for intestinal regeneration
News & Updates
Received a $256,000 grant from the National Science Foundation to develop a minimally-invasive, endoscopic version of the Eclipse XL1 System for pediatric and adult patients with SBS.
An in-depth look at the innovative Eclipse XL1 device that aims to promote intestinal tissue growth and reduce dependence on TPN.
Secured a significant grant to support the development of minimally-invasive SBS therapies.
Received a $256,000 grant from the National Science Foundation to develop a minimally-invasive, endoscopic version of the Eclipse XL1 System for pediatric and adult patients with SBS.
An in-depth look at the innovative Eclipse XL1 device that aims to promote intestinal tissue growth and reduce dependence on TPN.
Secured a significant grant to support the development of minimally-invasive SBS therapies.